文献速递骨质疏松与代谢性骨病

厘清骨质疏松患者的临床未治疗状态

Clarifying clinically treatment-naive status for osteoporosis patients.
PubMed 文献 · Osteoporos Int · 2026-02-17

本文讨论如何定义骨质疏松症的「临床未治疗」状态,提出对远程或短期既往暴露患者应归类为临床未治疗,并汇总关键试验方案和北美指南中的定义,给出针对高至极高骨折风险患者初始治疗的统一定义。

要点

  • 远程或短期既往骨质疏松治疗暴露不影响后续疗效,可视为临床未治疗。
  • 明确临床未治疗定义有助于极高骨折风险患者获得促骨形成治疗。
  • 提出基于既往药物类型和停药时间的统一定义以指导治疗序贯决策。

核心结论

  • 统一定义临床未治疗状态有助于多学科团队和医疗决策者做出治疗序贯决策。

研究设计与样本

  • 本文总结了已批准骨质疏松疗法关键试验方案和北美近期实践指南中临床未治疗的定义,并提出统一定义。

主要发现

  • 远程或短期既往骨质疏松治疗暴露后,骨密度和骨转换的治疗效应随时间消退,因此可将此类患者归类为临床未治疗。
  • 缺乏临床未治疗 clarity 可能使短期或远程既往暴露的极高骨折风险患者面临促骨形成治疗障碍。
  • 双膦酸盐因独特骨结合特性停药后抗骨吸收活性持续但有限,非双膦酸盐疗法停药后消退较快需及时转换。

关键数值与推荐

  • 口服双膦酸盐≥1年或接受≥1次年度静脉双膦酸盐剂量且停药≥2年者,定义为治疗未治。
  • 口服双膦酸盐>3个月且<1年并停药1-2年者,定义为治疗未治。
  • 口服双膦酸盐≤3个月后停药者,定义为治疗未治。
  • 末次地舒单抗注射≥12个月前,定义为治疗未治。
  • 停用阿巴洛肽、罗莫索单抗或特立帕肽≥12个月,定义为治疗未治。

临床怎么用

  • 临床中可将远程或短期既往骨质疏松治疗暴露的患者视为临床未治疗,以减少促骨形成治疗的准入障碍。
  • 根据既往药物类型和停药时间应用统一定义,辅助治疗序贯决策。

局限性

  • 长期双膦酸盐对骨强度和非典型股骨骨折易感性的潜在遗留效应超出本报告范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CLINICAL RELEVANCE: Although patients with remote or brief prior exposure to osteoporosis treatments are strictly not "treatment naive," osteoporosis treatment effects on bone mineral density and bone turnover resolve over time. It would therefore be useful to categorize patients with remote or brief prior exposure to osteoporosis treatment as "clinically treatment naive." This lack of clarity of who can be categorized as clinically treatment naive may disadvantage patients at very high fracture risk with brief or remote prior exposure who may face barriers to bone-building therapies. Access may be restricted to those who have never received treatment, based on the mistaken assumption that brief or remote prior exposure significantly impairs treatment response. Here, we summarize how clinically treatment-naive has been defined in protocols for pivotal trials of approved osteoporosis therapies and recent practice guidelines in North America. Consistent definitions are proposed for initial therapies for patients at high-to-very-high fracture risk. Bisphosphonates are discussed in greater detail owing to their unique bone-binding properties, leading to more persistent, albeit finite, antiresorptive activity after discontinuation. A discussion of possible lingering effects of long-term bisphosphonates on bone strength and predisposition to atypical femoral fractures was beyond the scope of this report. In contrast, non-bisphosphonate therapies resolve relatively rapidly after discontinuation, necessitating timely transition to another agent to prevent reversal of anti-fracture efficacy. OBSERVATIONS: Proposed definitions of treatment-naive for the therapies discussed here are treated with oral bisphosphonate for ≥ 1 year or received ≥ 1 annual IV bisphosphonate dose and discontinued ≥ 2 years ago; treated with oral bisphosphonate for > 3 months and < 1 year and discontinued 1-2 years ago; discontinued oral bisphosphonate after ≤ 3 months; received last denosumab injection ≥ 12 months ago; and discontinued abaloparatide, romosozumab, or teriparatide ≥ 12 months ago. CONCLUSIONS: In conclusion, a unified definition could aid multidisciplinary care teams and healthcare decision-makers in making treatment sequencing decisions.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kendler DL, Habert J, Khan AA, et al. Clarifying clinically treatment-naive status for osteoporosis patients. Osteoporos Int. 2026. PMID: 41701231. doi:10.1007/s00198-026-07864-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。